FIELD: biotechnology.
SUBSTANCE: method for producing an antibody-ligand conjugate, in which the ligand is a molecule capable of binding to the ASGPR receptor. The method includes the stages of ligand activation in the process of sequential interaction with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-hydroxysulfosuccinimide in phosphate or phosphate-buffered saline at pH 5.0-7.0 with the formation of N-hydroxysulfosuccinimide ester of the ligand and bioconjugation, during which the N-hydroxysulfosuccinimide ester of the ligand interacts with the primary amino group of the antibody in phosphate or phosphate-buffered saline at pH 7.2-7.4.
EFFECT: expanding the range of bioconjugation methods.
5 cl, 7 dwg, 3 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
CONJUGATE OF LUMINESCENT SILICON DIOXIDE NANOPARTICLES WITH RECOMBINANT SINGLE-DOMAIN C7B LAMA NANO-MONOANTIBODIES, CAPABLE OF SPECIFICALLY INTERACTING WITH RECOMBINANT HER2/NEU PROTEIN - ANALOGUE OF EPIDERMAL GROWTH FACTOR NATURAL RECEPTOR EGFR/ERBB OF HUMAN CELLS | 2017 |
|
RU2679075C1 |
METHOD FOR DOUBLE CONJUGATION FOR OBTAINING ANTIBODY-DRUG CONJUGATES | 2018 |
|
RU2771310C2 |
METHOD FOR CONJUGATION OF A POLYPEPTIDE | 2015 |
|
RU2715905C2 |
MATERIALS AND METHODS ASSOCIATED WITH LINKERS FOR USE IN DRUG AND PROTEIN CONJUGATES | 2015 |
|
RU2737553C2 |
LOW MOLECULAR WEIGHT LIGANDS OF ASIALOGLYCOPROTEIN RECEPTOR BASED ON QUINOLINE-4-CARBOXYLIC ACID | 2020 |
|
RU2769859C1 |
EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY | 2013 |
|
RU2652880C2 |
METHOD FOR CONJUGATION OF HUMAN HEAVY CHAIN CONSTANT FRAGMENT AND PEPTOID ANALOGUE OF AUTOANTIGEN MOG35-55 FOR MULTIPLE SCLEROSIS THERAPY | 2018 |
|
RU2724714C1 |
SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION BY MEANS OF GLYCOENGINEERING | 2014 |
|
RU2711935C2 |
TUMOR-SPECIFIC ANTI-EGFR ANTIBODY AND USE THEREOF | 2016 |
|
RU2730605C2 |
METHOD OF SYNTHESISING CONJUGATES OF GLYCOSEAMINOGLYCANES (GAG) WITH BIOLOGICALLY ACTIVE MOLECULES, POLYMER CONJUGATES AND THEIR RESPECTIVE APPLICATIONS | 2010 |
|
RU2530649C2 |
Authors
Dates
2023-11-08—Published
2022-11-30—Filed